What's Ailing OPK Stock?
Opko Health Inc. (NASDAQ:OPK) was down 18.5% by early afternoon trading on Friday as the company announced that its weekly injection to treat growth hormone deficiency failed to do so compared with a placebo in a late-stage trial, which propagated the OPK stock blowout.
The growth hormone, hGH-CTP, was unable to statistically change the amount of torso fat compared to a placebo. The test was meted out over 26 weeks and involved.
Den vollständigen Artikel lesen ...
Opko Health Inc. (NASDAQ:OPK) was down 18.5% by early afternoon trading on Friday as the company announced that its weekly injection to treat growth hormone deficiency failed to do so compared with a placebo in a late-stage trial, which propagated the OPK stock blowout.
The growth hormone, hGH-CTP, was unable to statistically change the amount of torso fat compared to a placebo. The test was meted out over 26 weeks and involved.
Den vollständigen Artikel lesen ...